SCHEDULE 13G/A: Schonfeld Strategic Advisors Discloses 2.82% Stake in Reviva Pharmaceuticals Holdings
Beneficial Ownership Report
Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting a 2.82% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2024.
Summary
- Schonfeld Strategic Advisors LLC, an investment adviser, reported beneficial ownership of 1,314,915 shares of common stock in Reviva Pharmaceuticals Holdings, Inc.
- This ownership represents 2.82% of Reviva Pharmaceuticals Holdings, Inc.'s common stock outstanding.
- The percentage is calculated based on 46,579,199 shares of common stock outstanding, as detailed in a prospectus supplement filed by the issuer on December 18, 2024.
- Schonfeld Strategic Advisors LLC holds sole voting power and sole dispositive power over all 1,314,915 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
Sentiment
Score: 5
Explanation: The document is a factual, routine ownership disclosure and does not convey positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
The document does not contain any forward-looking statements or guidance from the reporting person regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of passive beneficial ownership by an investment adviser, common in the financial industry. It does not provide specific insights into broader pharmaceutical industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, though passive, ownership stake by an institutional investor.
Key Dates
| Date | Description |
|---|---|
| 2024-12-16 | Date of prospectus supplement related to an offering by Reviva Pharmaceuticals Holdings, Inc. |
| 2024-12-18 | Date prospectus supplement was filed by Reviva Pharmaceuticals Holdings, Inc. with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 1 was signed by Schonfeld Strategic Advisors LLC. |
Keywords
Reviva Pharmaceuticals Holdings Inc., Schonfeld Strategic Advisors LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.